PROTAC EGFR degrader 14
Based on 1 Customer Validation
PROTAC EGFR degrader 14 is a EGFR PROTAC degrader, with a DC50 of 2.9 nM against EGFRL858R/T790M/C797S. PROTAC EGFR degrader 14 forms a stable ternary complex by bridging the ATP-binding pocket of the target protein EGFR with VHL E3 ubiquitin ligase, induces efficient and specific degradation of EGFR mutants via the ubiquitin-proteasome system, and ultimately induces cell cycle arrest and apoptosis. PROTAC EGFR degrader 14 can be used in studies related to non-small cell lung cancer carrying the EGFRC797S drug-resistant mutation.
(Pink: EGFR ligand (HY-143337); Blue: VHL ligand (HY-125845); Black: linker (HY-W004688)).
For research use only. We do not sell to patients.
- Purity : 99.26%
- Formula: C57H73N11O4S
- Molecular Weight:1008.33
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
EGFRL858R/T790M/C797S 2.9 nM (DC50) |
ERK |
Bax |
Bcl-2 |
p-STAT3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PC-9 | IC50 |
26.8 nM
|
Antiproliferative activity against human NSCLC PC9 (EGFRL858R/T790M/C797S) cells assessed as reduction in cell viability incubated for 3 days by CCK-8 assay.
Antiproliferative activity against human NSCLC PC9 (EGFRL858R/T790M/C797S) cells assessed as reduction in cell viability incubated for 3 days by CCK-8 assay.
|
40640988 |
| PC-9 | IC50 |
25.9 nM
|
Antiproliferative activity against human NSCLC PC9 (EGFRL858R/T790M/C797S) cells assessed as reduction in cell viability incubated for 7 days by CCK-8 assay.
Antiproliferative activity against human NSCLC PC9 (EGFRL858R/T790M/C797S) cells assessed as reduction in cell viability incubated for 7 days by CCK-8 assay.
|
40640988 |
| GES1 | IC50 |
>10 μM
|
Cytotoxicity against human gastric epithelial GES-1 cells assessed as reduction in cell viability incubated for 72 h by CCK-8 assay.
Cytotoxicity against human gastric epithelial GES-1 cells assessed as reduction in cell viability incubated for 72 h by CCK-8 assay.
|
40640988 |
| BEAS-2B | IC50 |
>10 μM
|
Cytotoxicity against human normal lung epithelial BEAS-2B cells assessed as reduction in cell viability incubated for 72 h by CCK-8 assay.
Cytotoxicity against human normal lung epithelial BEAS-2B cells assessed as reduction in cell viability incubated for 72 h by CCK-8 assay.
|
40640988 |
In Vitro
PROTAC EGFR degrader 14 (Compound 9ea) (4 nM-20 μM; 24 h) efficiently and selectively degrades EGFRL858R/T790M/C797S in PC9 (EGFRL858R/T790M/C797S) cells in a concentration-dependent manner, with a DC50 of 2.9 nM, whereas it shows no obvious degradation activity in A549 (EGFRWT) cells[1].
PROTAC EGFR degrader 14 (0.25 μM; 4-24 h) reduces EGFR fluorescence intensity in a time-dependent manner in PC9 (EGFRL858R/T790M/C797S) and PC9 (EGFRDel19/L858R/C797S) cells[1].
PROTAC EGFR degrader 14 (3-7 days) potently inhibits cell proliferation in PC9 (EGFRL858R/T790M/C797S) cells, with an IC50 of 26.8 nM (3 days)/25.9 nM (7 days); it exhibits extremely low cytotoxicity in normal human lung epithelial cells (BEAS-2B) and gastric epithelial cells (GES-1) (IC50 > 10 μM)[1].
PROTAC EGFR degrader 14 (0.1-5 μM; 24 h) dose-dependently induces G1/G0 cell cycle arrest, reduces S-phase cell population, concentration-dependently promotes early and late cell apoptosis, effectively inhibits EGFR and its downstream signaling pathways, and regulates apoptosis-related proteins in PC9 (EGFRL858R/T790M/C797S) and PC9 (EGFRDel19/T790M/C797S) cells, but exerts weak inhibitory effects in A549 (EGFRWT) cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC9 (EGFRL858R/T790M/C797S), PC9 (EGFRDel19/T790M/C797S), and A549 (EGFRWT) cells
-
Concentration:0.25 nM, 0.5 nM, 1 nM, 2 nM, 4 nM, 8 nM, 16 nM, 32 nM, 63 nM, 125 nM, 250 nM, 500 nM, 5 μM, 10 μM, 20 μM
-
Incubation Time:24 h
-
Result:Potently and dose-dependently degraded EGFR proteins harboring the C797S mutation (DC50 = 2.9 nM for the L858R mutant, DC50 = 21.6 nM for the Del19 mutant), while showing extremely weak degradation of wild-type EGFR (A549 cells), indicating high selectivity.
-
Cell Line:PC9 (EGFRL858R/T790M/C797S) and PC9 (EGFRDel19/L858R/C797S) cells
-
Concentration:0.25 μM
-
Incubation Time:4, 12, 24 h
-
Result:Induced the degradation of mutant EGFR proteins in a time-dependent manner, significantly weakening the fluorescence signal.
-
Cell Line:PC9 (EGFRL858R/T790M/C797S) and PC9 (EGFRDel19/L858R/C797S) cells
-
Concentration:0.1, 0.5, 1, 5 μM
-
Incubation Time:24 h
-
Result:Arrested the cell cycle at the G1/G0 phase in a dose-dependent manner and significantly reduced the proportion of cells in the S phase.
-
Cell Line:PC9 (EGFRL858R/T790M/C797S) and PC9 (EGFRDel19/L858R/C797S) cells
-
Concentration:0.1, 0.5, 1, 5 μM
-
Incubation Time:48 h
-
Result:Significantly promoted early and late apoptosis of resistant NSCLC cells in a concentration-dependent manner, outperforming osimertinib at the same concentrations.
-
Cell Line:PC9 (EGFRL858R/T790M/C797S), PC9 (EGFRDel19/L858R/C797S), and A549 (EGFRWT) cells
-
Concentration:0.01, 0.05, 0.25 μM
-
Incubation Time:24 h
-
Result:Effectively inhibited the activation of downstream EGFR signaling pathways (p-EGFR, p-AKT, p-Erk, p-STAT3) in mutant cells, upregulated the pro-apoptotic protein Bax, and downregulated the anti-apoptotic protein Bcl-2.
In Vivo
PROTAC EGFR degrader 14 (25-50 mg/kg; i.v.; once every other day; 2 weeks) exhibits favorable safety in healthy BALB/c mice, causing no significant body weight loss, no toxic damage to major organs including the heart, liver, spleen, lung, kidney and brain, and no adverse effects on hematological parameters and blood biochemical parameters[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 6-8 weeks old) were subcutaneously injected with PC9 (EGFRL858R/T790M/C797S) cells[1]
-
Dosage:25 mg/kg, 50 mg/kg
-
Administration:i.v.; once every other day; 16 days
-
Result:Achieved a 74.7% tumor growth inhibition (TGI) rate at 50 mg/kg, superior to the TGI rate of osimertinib at the same dose.
Significantly reduced average tumor weight compared to vehicle and osimertinib-treated groups at both doses.
Reduced EGFR protein levels in tumor tissues to 0.32 (25 mg/kg) and 0.35 (50 mg/kg) relative to vehicle.
Caused no significant body weight loss during treatment.
-
Animal Model:BALB/c nude (male, 6-8 weeks old)[1]
-
Dosage:25 mg/kg, 50 mg/kg
-
Administration:i.v.; once every other day; 2 weeks
-
Result:Caused no significant weight loss or abnormal behavior in mice, and no EGFR TKI-associated dose-limiting toxicities were observed.
Displayed no obvious toxicity to primary organs, including the heart, liver, spleen, lungs, kidneys, and brain.
Had no toxicity to the circulatory system and normal tissues and possessed a favorable safety profile.
Chemical Information
-
Appearance Solid
-
Molecular Weight 1008.33
-
Formula C57H73N11O4S
-
Color White to light yellow
-
SMILES
O=C(CCCCCCN1CCN(C2=CC=C(NC3=NC=C4C(N(C(CNC5=CC=CC=C5)=C4)C6CCCC6)=N3)C=C2)CC1)N[C@@H](C(C)(C)C)C(N7[C@H](C(NCC8=CC=C(C9=C(C)N=CS9)C=C8)=O)C[C@@H](O)C7)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (99.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9917 mL | 4.9587 mL | 9.9174 mL | 24.7935 mL |
| 5 mM | 0.1983 mL | 0.9917 mL | 1.9835 mL | 4.9587 mL | |
| 10 mM | 0.0992 mL | 0.4959 mL | 0.9917 mL | 2.4793 mL | |
| 15 mM | 0.0661 mL | 0.3306 mL | 0.6612 mL | 1.6529 mL | |
| 20 mM | 0.0496 mL | 0.2479 mL | 0.4959 mL | 1.2397 mL | |
| 25 mM | 0.0397 mL | 0.1983 mL | 0.3967 mL | 0.9917 mL | |
| 30 mM | 0.0331 mL | 0.1653 mL | 0.3306 mL | 0.8264 mL | |
| 40 mM | 0.0248 mL | 0.1240 mL | 0.2479 mL | 0.6198 mL | |
| 50 mM | 0.0198 mL | 0.0992 mL | 0.1983 mL | 0.4959 mL | |
| 60 mM | 0.0165 mL | 0.0826 mL | 0.1653 mL | 0.4132 mL | |
| 80 mM | 0.0124 mL | 0.0620 mL | 0.1240 mL | 0.3099 mL |